Member Info for Laura2022

These were the results for VLS 2mths ago

Does make you wonder why porky etc dont waste their knowledge on these horrific loss making companies that do nothing but give their directors £1mln+ wages and have no revenues,yet chose VAL and PYC who are fighting cancer and not far off breakeven

Revenue of £61k (HY2022: £48k) from engineering services.

· Grant income recognised of £8.7m (HY2022: £1.5m).

· Operating loss of £8.5m (HY2022: £6.7m) driven by increased activity reflecting the Altalto project entering FEED, scale up of manufacturing activity and project funding activities.

· Net loss before tax of £9.8m

Yes Stephen, given that VLS was acquired for £4.1mln this week and was losing £5mln per year plus had amnost no revenues . VLS was acquired for x 25+ its revenues

The same equation would put PYC at £15mln takeover versus £2.2mln current price

TRENCH123

20 Nov 2023 09:38

Continued ....

It is quite possible that the company could be acquired. JM in his April 2023 presentation referred to PYC having been approached by big pharma in this regard but it 'has not come to fruition up to this point in time'

I am happy to continue to hold my PYC shares (just under 1 million) and see how the story unfolds over the next few years

Be really good to see new people here, we've had some unsavoury people trying trying rubbish a company leading the UK foot against cancer and trying to swiften the process of getting drugs to market

I posted this yesterday

Why target a company who has one of lowest paid CEOs in small caps (many corrup CEOs have extortionate £350-300k+ salaries eg VRS LVCG PREMand dozens more. PYC CEO has achieved more revenues in the last 6yrs than the whole combined 17 years before him, has had no pay rise above his modest £130k salary at all and stated he will not have one until PYC is self sustaining ( VLS directors earn £1mln between 2 directors!)

They target a company that is growing revenues since the CEO took over and diversification of clients and have stated the are aiming for RECORD EVER revenues

A company that is seen as invaluable to over 60 clients many of whom on NASDAQ such as Bicycle

Chosen by Cancer Research UK to partner its UK work programmes

Aiming to fight Cancer (particularly)

Were on course for £900k+ revenues but 3 clients in Q1 2023 had a paused /be late(NOT cancelled ) on their work for PYC ( explained In Fridays Q and A)

People who spend time trying to rubbish the company clearly have a strange moral compass

There are some good summaries of PYC today and over the weekend

Also the excellent 50 minute presentation from last Friday was posted as a YouTube link by someone 2 days ago

Bongo lots going on and very small and undervalued £2mln market cap of which £700k+ is cash and pn target for £1mln revenues for this year

That's 2:1 !!

20% up

Great chart msuk how did you know ?

Stephen did a great summary about a month ago which I have used in the po

£1.9mln market cap with c.£750,000 cash and now a £130k Innovate Grant

£1mln pipeline of deals for 2023/24 on top of the 4 or 5 won since July 2023

Can now for the 1st time in 7 years (due to Brexit ) apply for Horizon EU funding which has earmarked £billions for technology and innovation ..the presentation on Friday said that the recent grant PYC won was won through Horizon applications

5 new contracts plus recommenced Merck revenues (€500,000 annually)

Hired 3 new personal to drive the business forward

Main points from the annual report below :

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

Device to measure blood counts

Feedback from clinicians suggests that enabling patients to undergo these diagnostic tests in a primary care or home setting would facilitate use of our tool and as such we are actively exploring opportunities to work with Beyond Blood.

Collaborations

we are open to and continue to explore other approaches including risk sharing and collaboration. An example of this includes the risk-sharing deal with ValiRx plc announced in February 2021 for which terms have been fully disclosed and which would be triggered by the receipt by ValiRx of licensing revenues related to VAL-201

I can't see it Stephen ?

Finally feels the post covid lull is going to start reversing and revenue generating bio techs should fair well

RUA is grateful news for bio techs

It rose yesterday and today for LOI for purchase orders of potentially £1.5mln versus a £10mln current market cap

That's about 15%

PYC for £2mln cap have potential revenues for year ended June 2024 of £1mln +

That seem very undervalued

This is the bit I thought might apply TO PYC

£16 million will be invested by the government for the trial through the National Institute for Health and Care Research (NIHR) and Prostate Cancer UK, who have led the development of the trial, will provide £26 million. The trial is due to start in spring 2024 with recruitment likely to begin in autumn 2024.  

The government has already opened 127 community diagnostic centres to offer quicker, more convenient checks outside of hospitals for conditions such as cancer, with over 5 million additional tests delivered so far. 

The major conditions strategy will also consider the prevention, diagnosis, treatment and management of conditions including cancer. The UK is already working with world-renowned scientists to deliver new cancer vaccine trials and is growing the size of the specialist workforce.

Https://www.gov.uk/government/news/biggest-prostate-cancer-screening-trial-in-decades-to-start-in-uk

Do you think PYC could be involved (not in the screening but the drug evaluation)

On International Men’s Day (19 November 2023), government joins Prostate Cancer UK to unveil £42 million screening trial to find ways of detecting country’s most common male cancer earlier Hundreds of thousands of men across the country will participate, with 1 in 10 participants set to be black men who have a much higher prostate cancer riskNHS England to carry out suite of improvements to men’s health pages online, and first ever Men’s Health Ambassador set to be appointed by government

Thousands of men’s lives could be saved, and their loved ones spared the tragedy of losing someone to cancer, as a major new prostate cancer screening trial is set to get under way in the UK backed by £42 million from the government and Prostate Cancer UK.  

The first-of-its-kind trial - called TRANSFORM - will use innovative screening methods like an MRI scan to detect prostate cancer, and it will see hundreds of thousands of men across the country participating.  

Prostate cancer is the most common cancer in men in the UK and has no screening programme. It usually has no symptoms until it has grown large and may be more difficult to treat and, sadly, 12,000 men die of it every single year.  

Why target a company who has one of lowest paid CEOs in small caps (many corrup CEOs have extortionate £350-300k+ salaries eg VRS LVCG PREMand dozens more

Why target a company that is growing revenues since the CEO took over and diversification of clients and have stated the are aiming for RECORD EVER revenues

A company that is seen as invaluable to over 60 clients many of whom on NASDAQ such as Bicycle

Chosen by Cancer research UK to partner

Aiming to fight Cancer

People who spend time trying to rubbish the company clearly have a strange moral compass

Abertyst

Out ofnnowhere he appeared 2 weeks ago having spent a year on NNN and previously FDBK and IQAI

Quite why out of all the 100s of small AIM companies he chose to target PYC

I filtered 2 weeks ago

Pyc have been approached by big pharma ?

For deals or takeover Trench ?

Hi Jimi

I think 2024 will ne the year

Most AIM companies are years away from breakeven

Also new office was to aid remote working

Jim says should save £30k-40k per annum and will be reviewed

Also interesting was that he and now Pete mention Project Optimus/FDA modelling expectations in everyclient discussions

We are processing the questions, we'll notify you once they become available.

Jim also mentioned that for the 1st time since Brexit 2016 UK companies like PYC cam now apply...in fact Jim said the recent project was via this route,he said clearly with dozens of countries being able to apply it is competitive but he seems hopeful of other projects

Details about Horizon below

Why apply for Horizon Europe funding

Horizon Europe is an EU research and innovation programme. It has a budget of €95.5 billion and runs until 2027.

The UK agreed a deal to associate to Horizon Europe on 7 September 2023.